Список литературы

1. Juhlin L. Treatment of psoriasis and other dermatoses with a single application of a corticosteroid left under a hydrocolloid occlusive dressing for one week. Acta Derm Venereol. 1989; 69 (4): 355 - 357.

2. Tzung T.Y., Liu Y.S., Chang H.W. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol. 2007; 156 (1): 191 - 192.

3. Chang A.Y., Werth V.P. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011; 13 (4): 300 - 307.

4. Winkelmann R.R., Kim G.K., Del Rosso J.Q. Treatment of cutaneous lupus erythematosus. Review and assessment of treatment benefits based on Oxford centre for evidence-based medicine criteria. J Clin Aesthet Dermatol. 2013; 6 (1): 27 - 38.

5. Скрипкин Ю.К., Бутов Ю.С., Хамаганова И.В. и др. Поражения кожи при болезнях соединительной ткани. В: Клиническая дерматовенерология./под ред. Ю. К Скрипкина, Ю.С. Бутова. - М.: ГЭОТАР-Медиа, 2009. Т.II. - С. 234 - 277.

6. Ruzicka T, Sommerburg C, Goerz G. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol. 1992; 127 (5): 513 - 518.

7. Wozniacka A., McCauliffe D.P. Optimal use of antimalarials in treating cutaneous lupus erythematosus. Am J Clin Dermatol. 2005; 6 (1): 1 - 11.

8. Kuhn A., Gensch K., Haust M. et al. Efficacy of tacrolimus 0,1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011; 65 (1): 54 - 64.

9. Barikbin B., Givrad S., Yousefi M. et al. Pimecrolimus 1% cream versus betamethasone 17-valerate 0,1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized, pilot study. Clin Exp Dermatol. 2009; 34 (7): 776 - 780.

10. Drake L.A., Dinehart S.M., Farmer E.R. et al. Guidelines of care for cutaneous lupus erythematosus: American Academy of Dermatology. J Am Acad Dermatol. 1996; 34 (5Pt1): 830 - 836.

11. Kuhn A., Ochsendorf F., Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus 2010; 19 (9): 1125 - 1136.

12. Boehm I.B., Boehm G.A., Bauer R.. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998; 18 (2): 59 - 62.

13. Wenzel J., Brahler S., Bauer R. et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005; 153 (1): 157 - 162.

14. Kuhn A., Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014; 48 - 49: 14 - 19.

15. Gronhagen C.M., Nyberg F. Cutaneous lupus erythematosus: an update. Indian Dermatol Online J. 2014; 5 (1): 7 - 13.

16. Pinto-Almeida T., Sanches M., Alves R., Selores M. Vesico-bullous subacute cutaneous lupus erythematosus - an uncommon entity successfully treated with dapsone and hydroxychloroquine. Dermatol Online J. 2012; 18 (8): 13.

17. Капкаев Р.А., Селисский Г.Д., Адо В.А. Диспансеризация при кожных и венерических заболеваниях. Ташкент: Медицина, 1989. - 184 с.

18. Moura Filho J.P., Peixoto R..L, Martins L.G. et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol. 2014; 89 (1): 118 - 125.

19. Biazar C., Sigges J., Patsinakidis N. et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013; 12 (3): 444 - 454.

20. Kuhn A., Aberer E., . et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017; 31 (3): 389 - 404.

21. Sigges J., Biazar C., Landmann A. et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013; 12: 694 - 702.

22. Wenzel J., Brahler S., Bauer R. et al. Ef cacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005; 153 (1): 157 - 162.

23. Свинцицкий А.С. Системная красная волчанка: особенности клинической симптоматики. Doctor. 2002; 1: 22-6.

24. Главинская Т.А. Лечение и профилактика красной волчанки и склеродермии: Учеб. пособие. Н. Новгород: НГМА; 2000.

25. Бертсиас Г.И. Рекомендации EULAR по лечению системной красной волчанки. Научно-практическая ревматология. 2008; 1: 93-6.

26. Белик И.Е. Кожная красная волчанка: классификация, диагностика, тактика ведения больных. Дерматология та венерология. 2009; 3: 44 - 50.

27. Crowson A.N., Magro C.M. Cutaneous histopathology of lupus erythematosus. Diagnostic Histopathology. 2009; 15 (4): 157 - 185. https://doi.org/10.1016/j.mpdhp.2009.02.006

28. Ellis F.A., Bundick W.R.. Histology of lupus erythematosus. Ama Arch Derm Syphilol. 1954; 70 (3): 311 - 324. doi: 10.1001/archderm.1954.01540210051009.

29. Bharti S., Dogra S., Saikia B. et al. Immunofluorescence profile of discoid lupus erythematosus. Indian J Pathol Microbiol. 2015; 58 (4): 4794 - 4782

30. Isfer RS, Sanches , Festa Neto C, et al. Direct immunofluorescence in lupus erythematosus (LE). Sao Paulo Med J. 1996; 114 (2): 1141 - 1147. doi: 10.1590/s1516-31801996000200007

31. Jha AK, Sonthalia S, Sarkar R. Dermoscopy of discoid lupus erythematosus. Indian Dermatol Online J. 2016; 7: 458

32. Lallas A., Apalla Z., Lefaki I. et al. Dermoscopy of discoid lupus erythematosus. Br J Dermatol. 2013; 168 (2): 284 - 288

33. Lai N.S., Tsai T.Y., Koo M. et al. Patterns of ambulatory medical care utilization and rheumatologist consultation predating the diagnosis of systemic lupus erythematosus: A National population-based study. PloS One. 2014; 9 (7): e101485.10.1371/journal.pone.0101485.

34. Sivaraj R.R., Durrani O.M., Denniston A.K. et al. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007; 46 (12): 1757 - 1762.

35. Злобина Т.И., Казанцева Н.Ю. Трудная диагностика системной красной волчанки. Сибирский медицинский журнал. 2015; 135 (4): 114 - 117.

36. Насонов Е.Л, Шекшина С.В., Клюквина Н.Г., Насонова В.А. Новые направления фармакотерапии системной красной волчанки (опыт применения микофенолата мофетила). Клиническая медицина. 2002; 4: 26 - 30.

37. Клюквина Н.Г. Алгоритм лечения системной красной волчанки. Медицинский совет. 2016; (8): 103 - 109.

38. Рациональная фармакотерапия заболеваний кожи и инфекций, передаваемых половым путем: Рук. для практикующих врачей.//А.А. Кубанова, В.И. Кисина, Л.А. Блатун, А.М. Вавилов и др.; под общ. ред. А.А. Кубановой, В.И. Кисиной. М.: Литерра, 2005; 882 с.

39. Tsang V., Leung A.K., Lam J.M. Cutaneous lupus erythematosus in children. Curr Pediatr Rev. 2021; 17 (2): 103 - 110. doi: 10.2174/1573396317666210224144416.

40. Arkin L.M., Buhr K., Brandling-Bennett H., Chiu Y., Chong B., Curran M. et al. Practice-based differences in paediatric discoid lupus erythematosus. Br J Dermatol. 2019; 181 (4): 805 - 810. doi: 10.1111/bjd.17780.

41. Ezeh N, Ardalan K, Buhr KA, Nguyen C, Al Ahmed O, Ardoin SP et al. Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. J Am Acad Dermatol. 2022 Sep; 87(3): 559 - 566. doi: 10.1016/j.jaad.2022.04.028.

42. Meurer M. Childhood discoid lupus erythematosus and antimalarials. Dermatology. 2003; 207(2): 133. doi: 10.1159/000071781.

43. Адаскевич В.П. Наружная кортикостероидная терапия дерматозов. Рецепт. 2006: 3 (47): 67 - 71.

44. Lim D, Hatami A, Kokta V, Piram M. Linear cutaneous lupus erythematosus in children-report of two cases and review of the literature: A case report. SAGE Open Med Case Rep. 2020 Dec 9; 8: 2050313X20979206.

45. Iorizzo M, Misciali C, Lorenzi S. A 14-year-old boy with an irregularly bordered, erythematous, alopecic patch of the scalp. Int J Trichology. 2016; 8 (3): 150 - 152.

46. Гайнулин Ш.М., Гребенюк В.Н., Гришко Т.Н., Бассе Ф.Б. Особенности клиники дискоидной красной волчанки у детей. Вестник дерматологии и венерологии. 2010; 4: 55 - 59.

47. Гребенюк В.Н., Турбовская С.Н., Гришко Т.Н. и др. Дискоидная красная волчанка у девочки 2 лет. Клиническая дерматология и венерология. 2017; 16 (2): 19 - 23.

48. Котрехова Л.П., Вашкевич А.А. Опыт применения метилпреднизолона ацепоната в терапии опухолевидной красной волчанки. Вестник дерматологии и венерологии. 2015; (4): 132 - 136.

49. Tlacuilo-Parra A., , . et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford). 2005; 44 (12): 1564 - 1568.

50. Kawachi Y., Taguchi S., Fujisawa Y. et al. Linear childhood discoid lupus erythematosus following the lines of Blaschko: successfully treated with topical tacrolimus. Pediatr Dermatol. 2011; 28 (2): 205 - 207.

51. McCauliffe D.P. Cutaneous lupus erythematosus. Semin Cutan Med Surg. 2001; 20 (1): 14 - 26.

52. Хайрутдинов В.Р., Белоусова И.Э. Современные представления о кожных формах красной волчанки. Opinion Leader. 2020. N 10 (39): 60 - 66.

53. Chang A.Y., Piette E.W., Foering K.P. et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011; 147 (11): 1261 - 1267.

54. Siamopoulou-Mavridou A, Stefanou D, Drosos AA. Subacute cutaneous lupus-erythematosus in childhood. Clin Rheumatol. 1989; 8 (4): 533 - 537.

55. Viardot-Helmer A, Deisz S, Baron JM, Megahed M, Ott H. Lupus-Pannikulitis im Adoleszentenalter [Lupus panniculitis in adolescence]. Hautarzt. 2007; 58 (11): 920 - 992. German.

56. Klebes M., Wutte N., Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? A retrospective analysis of 34 patients and a review of the literature. Dermatology. 2016; 232 (1): 91 - 96.

57. Nutan F., Ortega-Loayza A.G. Cutaneous lupus: A brief review of old and new medical therapeutic options. J Investig Dermatol Symp Proc. 2017 Oct; 18 (2): S64 - S68. doi: 10.1016/j.jisp.2017.02.001

58. Huber A., , Bauer R. et al. Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. Br J Dermatol. 2006; 155 (4): 861 - 862.

59. Wolverton S.E. Monitoring for adverse effects from systemic drugs used in dermatology. J Am Acad Dermatol. 1992; 26: 661 - 679.

60. Wolverton S.E., Remlinger K. Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs. Dermatol Clin. 2007; 25 (2): 195 - 205.

61. Green M, Williams L, Boh E, Kuraitis D. Utility of hydroxychloroquine laboratory monitoring in dermatologic and rheumatologic patients. Arch Dermatol Res. 2024 May 22; 316(5): 194.

62. Fernandez AP. Updated recommendations on the use of hydroxychloroquine in dermatologic practice. J Am Acad Dermatol. 2017; 76 (6): 1176 - 1182.

63. Molinelli E., Paolinelli M., Campanati A. et al. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019; 15 (5): 367 - 379.

64. Zhu Y.I., Stiller M.J. Dapsone and sulphones in dermatology: Overview and update. J Am Acad Dermatol. 2001; 45 (3): 420 - 434.

65. Hajar T., Latour E.J., Haynes D. et al. Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohort. J Dermatolog Treat. 2022; 33 (4): 2161 - 2167.

66. Petersen M.P., Moller S., Bygum A. et al. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupuse: A nationwide cohort study in Denmark. Lupus. 2018; 27 (9): 1424 - 1430.

67. Gronhagen C.M., Fored C.M., Granath F., Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: A population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011; 164 (6): 1335 - 1341.

68. Теплюк Н.П., Грабовская О.В., Ражева П.А. Клинический случай волчаночного панникулита. Российский журнал кожных и венерических болезней. 2020; 23 (5): 334 - 340.

69. Fayard D., Franc s C., Amoura Z. et al. Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. J Am Acad Dermatol. 2022; 87 (2): 323 - 332.

70. Новоселецкая А.И., Белазарович А.А. Красная волчанка в практике врача-дерматолога "Dermatovenereology. Cosmetology", 2020, volume 6, N 3.